IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Summary

This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).

Timeline

Start

2020-07-27

Primary completion

2026-05-31

Completion

2026-09-30

Drugs

Indications